CD93

Sarah Silbiger/Getty Images The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week. August 26 Incyte announced that the FDA has approved Pemazyre (pemigatinib) for the treatment of relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangements. The drug is a selective FGFR inhibitor. The approval marks the first and only targeted treatment for this indication, Incyte stated. It is also the second approval for Pemazyre, which already has FDA authorization for adults previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement. Inhibikase Therapeutics received the go-ahead from the FDA to launch a study of IkT-001Pro for chronic myelogenous leukemia. IkT-001Pro is a prodrug formulation of imatinib mesylate and is designed to improve the safety of Gleevec (imatinib). Suzhou Junjing Biomedical Technology Co.’s IND for JS110 was approved by the FDA. The drug is a small molecule inhibitor of the nuclear export protein XPO1 for advanced tumors. August 25 Iovance Biotherapeutics initiated a rolling BLA submission to the FDA for li a tumor infiltrating lymphocyte therapy, in advanced melanoma patients. The therapy is intended for patients who have progressed on or after previous anti-PD-1/L1 therapy, are BRAF mutation positive and have previously received BRAF or BRAF/MEK inhibitor therapy. Century Therapeutics received the green light from the FDA to proceed with its ELiPSE-1 trial of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies. CNTY-101 is an allogeneic cell therapy engineered with four complementary functionalities, including a CD19 CAR for tumor targeting, IL-15 support for enhanced persistence, Allo-Evasion technology to prevent host rejection and enhanced persistence. It also has a safety switch to eliminate the drug if necessary. Therapeutic Solutions International filed an amendment with the FDA regarding its currently open Phase III trial. The company is requesting that eligibility be expanded to include all patients suffering from acute respiratory distress syndrome (ARDS) regardless of cause. It is currently only recruiting patients with advanced ARDS caused by COVID-19. B.More reported the FDA approved its IND application to launch a Phase IIb trial of SYNP-101 (psilocybin) for patients with alcohol use disorder. The trial is expected to start in early 2023. August 24 Calyptus Pharmaceuticals’s Abbreviated NDA (ANDA) for Brovana (arformoterol tartrate inhalation solution) was approved by the FDA. The drug, co-developed with VistaPharm, is indicated for the long-term, twice-daily maintenance treatment of bronchoconstriction in COPD patients, including chronic bronchitis and emphysema. Surgalign Holdings reported FDA 510(k) clearance of the Cortera Spinal Fixation System. It will integrate the system with the HOLO Portal surgical guidance system. Tachyon Therapeutics received the go-ahead from the FDA to initiate a Phase Ia trial of TACH101 for advanced solid tumors. The drug is a KDM4 inhibitor. Ainos submitted an IND to the FDA for a Phase II trial of Veldona, a low-dose oral interferon-alpha formulation, for mild symptoms related to COVID-19. August 23 Foghorn Therapeutics announced that the FDA placed a full clinical hold on a Phase I dose escalation study of FHD-286 in relapsed or refractory acute myelogenous leukemia and myelodysplastic syndrome. The drug is a BRG1/BRM inhibitor. The hold was based on a death in the study, but it has not been determined if it is related to the therapy or the disease. Jaguar Health reported the FDA has accepted its application for review for Orphan Drug Designation for Crofelemer. The drug is being evaluated for a rare congenital diarrheal disorder, microvillus inclusion disease (MVID). K36 Therapeutics received the green light from the FDA to run a Phase I trial of KTX-1001 in patients with relapsed and refractory multiple myeloma, enriching for patients with the t(4;14) genetic translocation. KTX-1001 is a small molecule methyltransferase inhibitor of the multiple myeloma SET domain known as MMSET. Abbott Laboratories’ Proclaim Plus spinal cord stimulation system featuring FlexBurst360 therapy was approved by the FDA. The product offers pain coverage across up to six areas of the trunk and/or limbs. Synlogic reported the FDA granted Fast Track designation to its SYNB1353 for the treatment of homocystinuria. iECURE announced the FDA has granted Rare Pediatric Disease Designation to GTP-506. The drug is being developed to treat Ornithine Transcarbamylase (OTC) deficiency. August 22 Pfizer was instructed by the FDA to run a clinical trial to evaluate an additional course of its antiviral combination therapy Paxlovid in people who experienced COVID-19 rebound infections. The company is expected to have initial data by Sept. 30, 2023. Pharvaris reported the FDA has placed a clinical hold on the trials of PHA121 under two Pharvaris INDs for treatment of hereditary angioedema (HAE). The hold is based on reviews of nonclinical data. Ocelot Bio’s OCE-205 received Orphan Drug Designation from the FDA for treatment of hepatorenal syndrome. It is currently enrolling patients in a Phase II trial of the drug in hepatorenal syndrome with acute kidney injury. Thermedical received the green light from the FDA to run a trial for SERF ablation to treat ventricular tachycardia patients resistant to conventional treatment. SERF ablation with the Durablate catheter will be the focus of the study. DynamiCure was cleared by the FDA to run a Phase I trial of DC-6001, a therapeutic antibody against CD93, in adults with a range of advanced cancers. Insulet received clearance of its Omnipod 5 Automated Insulin Delivery System for children aged two years and older with Type 1 diabetes. Minerva Neurosciences submitted a New Drug Application to the FDA for roluperidone for negative symptoms in patients with schizophrenia.

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic antibody candidates, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to advance the first monoclonal antibody candidate from the company’s DC-6001 anti-CD93 development program into a Phase 1 study (NCT05496595). The study is designed to evaluate the safety and efficacy of DCBY02 in adult patients with a wide range of advanced cancers. CD93 is a novel target that has been shown to play a critical role in the abnormal development of tumor vasculature, dysfunction that often creates a hypoxic tumor microenvironment and limits the efficacy of cancer therapies, including checkpoint inhibitors. DynamiCure obtained exclusive global rights to CD93 from the laboratories of world-renowned immunologist and oncologist and DynamiCure’s scientific co-founder, Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology at Yale University, and Yuwen Zhu, PhD, Associate Professor of Surgical Oncology at the University of Colorado Anschutz Medical Campus. DynamiCure’s DC-6001 program consists of two anti-CD93 monoclonal antibodies, each of which has demonstrated distinct in vitro and in vivo properties and the ability to block different epitopes of CD93 in pre-clinical development. The Phase 1 program consists of two parts: a dose-escalation phase (Part 1) to determine a recommended Phase 2 dose (RP2D), followed by a dose-expansion phase (Part 2) at the RP2D. Both parts aim to include adult patients with a variety of locally advanced or metastatic solid tumors. DynamiCure plans to submit the IND for the second monoclonal antibody from the DC-6001 program, DCSZ11, in the fourth quarter of 2022. “Targeting this previously unexplored pathway at the crossroads of angiogenesis and the Cancer Immunity Cycle creates the potential to benefit cancer patients in need of new, impactful treatment options by more selectively targeting malignant tumor vasculature,” said Oliver Rosen, MD, President & Chief Medical Officer of DynamiCure. “A significant milestone for DynamiCure, advancement of our first candidate into clinical development is a testament to the thorough scientific foundation underlying this novel target combined with the hard work and dedication of our team, who were able to rapidly progress multiple innovative programs in just a few short years. We look forward to initiating the first part of the Phase 1 study in the coming months, as we finalize our network of cancer research centers participating in the trial.” Dr. Chen also commented on the news: “It has been known for two decades that inadequate tumor vascularization deteriorates the outcome of chemotherapeutic agents due to hypoxia - our research has shown that normalization of malignant tumor vasculature is required to turn the tumor microenvironment from immunosuppressive to immunostimulatory. We believe that targeting the CD93 pathway holds the potential to improve hypoxia and enhance the efficacy of other anti-cancer agents. The approval of this IND marks an important step forward in our ongoing research into pioneering ways to harness the immune system and treat a number of difficult-to-treat cancers. I look forward to continuing to collaborate with the DynamiCure team as they work to advance this and additional internal programs.” About DynamiCure DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates. For more information on our capabilities, programs, and team, please visit . Contacts: Oliver Rosen M.D. (Corporate) President & Chief Medical Officer contact@dynamicure.com Susan Heins (Media) 864-346-8336 susanheins1@gmail.com